PDE4A and chronic obstructive pulmonary disease: Consistently with observations with the oral PDE4 inhibitor roflumilast in COPD, the chronic bronchitis phenotype was found to be a determinant of response in terms of exacerbation rate reduction (Singh et al., 2020c).